| アブストラクト | OBJECTIVES: To determine whether the timing and duration of statin exposure following total hip/knee arthroplasty (THA/TKA) influence the risk of revision arthroplasty. METHODS: Subjects from the Clinical Practice Research Datalink, a large population-based clinical database, who had THA/TKA from 1988 to 2016, were included. Propensity score adjusted Cox regression models were used to determine the association between statin exposure and the risk of revision THA/TKA, (1) at any time, and (2) if first exposed 0-1, 1-5, or > 5 years following THA/TKA. We also investigated the effect of duration of statin exposure (< 1, 1-2, 2-3, 3-4, 4-5, > 5 yrs). RESULTS: The study included 151,305 participants. There were 65,032 (43%) exposed to statins during followup and 3500 (2.3%) had revision arthroplasty. In a propensity score adjusted model, exposure to statins was associated with a reduced risk of revision arthroplasty (HR 0.82, 95% CI 0.75-0.90). Participants first exposed within 1 year and between 1 and 5 years following THA/TKA (vs unexposed) had a reduced risk of revision arthroplasty (HR 0.82, 95% CI 0.74-0.91 and HR 0.76, 95% CI 0.65-0.90, respectively). In relation to duration of statin therapy, participants exposed for more than 5 years in total (vs < 1 yr) had a reduced risk of revision (HR 0.74, 95% CI 0.62-0.88). CONCLUSION: Statin therapy initiated up to 5 years following THA/TKA may reduce the risk of revision arthroplasty. |
|---|
| 組織名 | From the Arthritis Research UK Centre for Epidemiology, Division of;Musculoskeletal and Dermatological Sciences, School of Biological Sciences,;Faculty of Biology, Medicine and Health, The University of Manchester,;Manchester; Institute of Genetic Medicine, Newcastle University; The Centre for;Hip Surgery, Wrightington Hospital, Wrightington Wigan and Leigh National Health;Service (NHS) Foundation Trust, Wigan; UK National Institute for Health Research;(NIHR) Manchester Biomedical Research Centre, Manchester University NHS;Foundation Trust, Manchester Academic Health Science Centre, Manchester;;Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK.;M.J. Cook, MSc, Arthritis Research UK Centre for Epidemiology, Division of;Faculty of Biology, Medicine and Health, The University of Manchester; A.K.;Sorial, MRCS, Institute of Genetic Medicine, Newcastle University; M. Lunt, PhD,;Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and;Dermatological Sciences, School of Biological Sciences, Faculty of Biology,;Medicine and Health, The University of Manchester, Manchester Academic Health;Science Centre; T.N. Board, MD, The Centre for Hip Surgery, Wrightington;Hospital, Wrightington Wigan and Leigh NHS Foundation Trust; T.W. O'Neill, MD,;Dermatological Sciences, The University of Manchester, and NIHR Manchester;Biomedical Research Centre, Manchester University NHS Foundation Trust,;Manchester Academic Health Science Centre, and Department of Rheumatology,;Salford Royal NHS Foundation Trust.;neill@manchester.ac.uk.;Salford Royal NHS Foundation Trust. neill@manchester.ac.uk. |
|---|
